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Background – Antimicrobial resistance is a problem in human and animal healthcare. Honey may be used for its
wound healing properties and antimicrobial effects.
Objective – To investigate the antimicrobial activity of two commercially available medical grade honeys (MGHs)
against Staphylococcus spp. and Pseudomonas spp. isolates.
Methods and materials – Two formulations, MGH1 (40% w/v honey) and MGH2 (80% w/v Manuka honey),
were tested in vitro for minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC)
against 11 Staphylococcus and 11 Pseudomonas isolates at low [1.5 9 104 colony forming units (cfu)/well] and
high (1.5 9 106 cfu/well) concentrations of inoculum, representing systemic and cutaneous bacterial loads dur-
ing infection, respectively.
Results – MGH2 showed a lower MIC against staphylococci than MGH1, although this was not statistically sig-
nificant. MGH1 had stronger bactericidal effects against staphylococci than MGH2, although this effect was sta-
tistically significant only at the higher bacterial concentration (P < 0.01). For Pseudomonas spp., MGH1 had
significantly higher antimicrobial activity (both MIC and MBC) than MGH2 against all isolates tested and at both
bacterial concentrations (P < 0.05).
Conclusions and clinical importance – Both MGHs were effective in vitro against common cutaneous patho-
gens including meticillin-resistant staphylococci and Pseudomonas species. The higher efficacy of the MGH1 for-
mulation against Pseudomonas and its consistent effects against staphylococci, while containing only half of the
amount of honey compared to MGH2, invites further investigation of the mechanisms and clinical applications of
MGH1.
Introduction
Staphylococcus spp. and Pseudomonas aeruginosa are
among the most common opportunistic pathogens of
humans and domestic animals, and possess the ability to
persist in harsh environments and to develop resistance
to many antimicrobials.1–3 With both bacterial genera dis-
playing increasingly high-risk lineages both in human
patients and veterinary species there is growing interest
in assessing the efficacy of alternative therapeutic agents
against antimicrobial-resistant strains.4 Several sub-
stances exist that have antimicrobial activity including
honey, phytochemicals, essential oils and phages. Honey
has seen renewed interest in recent times including for
infected wounds and those associated with antimicrobial-
resistant bacteria.5,6 Whereas standard antimicrobials
possess highly specialized mechanisms of action, the
antibacterial effects of honey are based on a wide range
of properties.5,7,8
Different medical grade honeys (MGHs) exist. Two
formulations used in wound care are MGH1 (L-Mesitran
Soft, Triticum; Maastricht, the Netherlands) and MGH2
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(Medihoney; Integra Life Sciences, Plainsboro, NJ,
USA). Apart from the honey, MGH1 contains additional
healing components including vitamins C and E.2,10–12
The antimicrobial activity of MGH1 against S. pseudin-
termedius and Malassezia pachydermatis has been
investigated previously, and it was reported that MGH1
had stronger antimicrobial activity against both patho-
gens than honey alone, which suggests that the other
components may enhance the antimicrobial activity.2
MGH2 contains pure monofloral Leptospermum scopar-
ium (Manuka) honey. A major difference is that MGH2
contains Manuka honey, which exerts antimicrobial
effects mainly based on methylglyoxal, whereas other
honeys primarily exert antimicrobial activity via hydro-
gen peroxide.13–15 Manuka honey was the first honey
to be extensively investigated,5,16–20 but other types of
honey have been compared to it and found to have a
similar or even stronger antimicrobial activity.21–23 A
100-fold difference in antimicrobial activity has been
reported between different types of honey, supporting
the importance of selecting the most potent product
for any given application.9
The present study sought to evaluate the bacterio-
static (minimum inhibitory concentration; MIC) and bac-
tericidal (minimum bactericidal concentration; MBC)
concentrations of two commonly used MGH formula-
tions against clinical isolates of two skin pathogens
(Staphylococcus spp. and Pseudomonas spp.). Two
concentrations of bacteria were used for testing accord-
ing to the “105 guideline”; a lower concentration to rep-
resent a systemic bacterial load during infection and a
higher concentration to represent bacterial load curing
cutaneous infection.24–28
Methods and materials
Medical honey formulations
The two MGH formulations, MGH1 and MGH2, were as follows:
MGH1 consisted of 40% MGH, propylene glycol, lanolin,
PEG4000 and vitamins C and E (L-Mesitran Soft); MGH2 con-
sisted of 80% MGH with a hydrocolloidal gelling agent (Medi-
honey). Percentages (w/v) of MGH formulation that have
antimicrobial effects are reported, rather than the percentage of
honey in the products.
Bacterial isolates
Clinical isolates included 11 staphylococci (S. aureus, S. epider-
midis, S. pseudintermedius and S. schleiferi) and 11 Pseudomonas
(P. aeruginosa and P. fluorescens) that had been characterized in
previous studies at the Laboratory of Antibiotic Resistance – Fac-
ulty of Veterinary Medicine, University of Lisbon (FMV-UL),29–33
Instituto de Higiene e Medicina Tropical, Universidade NOVA de
Lisboa (IHMT-UNL)29,30 and from the Genevet bacterial Biobank.
Bacterial strains were inoculated in Columbia 5% blood agar
(bioMerieux; Lisbon, Portugal) and incubated aerobically at 37°C
for 18 h. For all isolates, the susceptibility profile against 31 antimi-
crobial agents was determined (see Tables S1 and S2 in Support-
ing information).
Susceptibility phenotypes were evaluated by determination of
the MIC using the microdilution system SIEMENS Microsan
B1016-173 POS MIC Panel Type 33 (Siemens Healthcare Diag-
nostics; West Sacramento, CA, USA) and B1016-175 NEG MIC
Panel Type 44 (Siemens Healthcare Diagnostics) for Staphylococ-
cus spp. and Pseudomonas spp. isolates, respectively. The
staphylococcal isolates originated from human and canine skin
infections; the Pseudomonas spp. isolates originated from canine
otitis externa cases, they often exhibited resistance to aminogly-
cosides, fluoroquinolones or other classes of antimicrobials (often
multidrug resistant, MDR). The main characteristics of these iso-
lates are summarized in Table 1. Of note, MDR and meticillin-re-
sistant (MR) staphylococcal isolates [MR Staphylococcus aureus
(MRSA) ST22- SCCmec IV and MR Staphylococcus pseudinter-
medius (MRSP) ST71-SCCmec II-III] from pyoderma cases in
dogs and MRSA SM39 and SM52 isolates which harboured the
biocide resistance genes qacA and smr, respectively, were
included.29,30
Determination of the MICs and MBCs of MGH1 and
MGH2
The methods for the MIC and MBC determinations were adapted
from several Clinical Laboratory Standard Institute (CLSI) guide-
lines.34–36 Stock solutions of MGH1 and MGH2 were prepared by
dissolving the product in sterile distilled water using two-fold
serial dilutions, resulting in 40%, 20%, 10%, 5% and 2.5% (w/v)
MGH1 and MGH2. The MGH stock solutions were prepared
immediately before the antibacterial assays. An inoculum of each
isolate was prepared and the turbidity of the suspension adjusted
to achieve 0.5 McFarland [equivalent to that of 1.5 9 108 colony-
forming units (CFU/mL)] and checked to have an absorbance of
0.150 by UV-visible spectrophotometer at a wavelength of
600 nm.
The MICs of both MGH1 and MGH2 for the different isolates were
determined by the broth dilution method using 96 well microtitre
plates as follows: 100 lL of Mueller–Hinton Broth medium (MHB,
Oxoid; Madrid, Spain) was introduced to each well, and 100 lL of the
MGH1 or MGH2 were added in the first column of the 96 well micro-
titer plates, mixed and serially two-fold diluted in the subsequent
wells. Then 10 lL of the adjusted bacterial concentration inoculums
of the 11 Staphylococcus spp. isolates and 11 Pseudomonas spp.
isolates were added to the test wells, in triplicate, in order to obtain a
final concentration of 1.5 9 104 cfu and 1.5 9 106 cfu per well,
defined as “lower” and “higher” inoculums concentrations, respec-
tively. The positive control wells contained MHB with the adjusted
lower and higher bacterial inocula concentrations in order to check
the bacterial viability, whereas the negative control wells contained
only sterile MHB. Positive and negative control wells were per-
formed in triplicate. The microtitre plates were then incubated at
37°C for 18 h. One microlitre of the negative control, positive con-
trols and each of the bacterial concentration inoculums were subcul-
tured before incubation in Tryptic soy agar (TSA; Oxoid) plates to
assess the culture purity and number of cfu/mL in each well after
incubation at 37°C for 18 h and thus to double-check the initial inocu-
lum concentrations. Also, for the final validation of the initial bacterial
suspension concentrations in the positive controls, the growth of 30–
300 cfus and above 300 cfus were accepted for 1.5 9 105 cfu/mL
(1.5 9 104 cfu per well) and to 1.5 9 107 cfu/mL (1.5 9 106 cfu per
well), respectively. After incubation, bacterial growth was observed
visually by the turbidity of the wells. The lowest concentration of the
MGH1 and MGH2 that showed no turbidity was designated as the
MIC.
The MBCs also were determined for the two different bacterial
inoculum concentrations. The MBC was determined by adding 10 lL
of the concentration which did not show any growth after incubation
during MIC testing, to TSA plates. TSA plates were then incubated at
37°C for 18 h in the absence of the MGH products. The lowest con-
centration that killed 99.9% of the initial bacterial population and in
which the plates showed no growth of colonies on the TSA agar,
was recorded as the MBC.36
Statistical analysis
Data were analysed using PRISM 8.0.1 software (GraphPad; San
Diego, CA, USA). The statistical significance of differences between
MGH1 and MGH2 concerning MIC and MBC, for each of the two
concentrations separately, were evaluated using the nonparametric
Wilcoxon matched-pairs signed rank test; no values were left out
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during analysis. Results were considered significantly different for
P < 0.05.
Results
In vitro efficacy of MGHs against staphylococci
The MIC data for MGH1 and MGH2 at low and high bac-
terial loads for all staphylococcal isolates are presented in
Figure 1. For MGH1, independently of the inoculum con-
centration, bacteriostatic effects were observed at 10%
(w/v) for all staphylococcal isolates, except for MRSP
FMV 4877/10. For this isolate, at the high inoculum con-
centration, a bacteriostatic effect of MGH1 was only
observed at 20% (w/v). A higher variation in MIC values
was observed for MGH2, although for most isolates a
bacteriostatic effect also was achieved at 10% (w/v). At
the low inoculum concentration, three isolates presented
a MIC of 2.5% (w/v), whereas two isolates presented
MICs of 5% (w/v). At the high bacterial load, one isolate
displayed a MIC of 2.5% (w/v), whereas two had a MIC
of 5% (w/v). Again, isolate MRSP FMV 4877/10 pre-
sented a MIC of 40% (w/v) for MGH2 at high inoculum
concentration.
Overall, higher concentrations of MGH1 were needed
to exert bacteriostatic effects against some staphylococ-
cal isolates when compared to MGH2. However, MGH1
had more consistent MIC values and demonstrated less
variation against the different isolates. No statistically sig-
nificant differences were found between MGH1 and
MGH2 regarding the MICs (P = 0.0625 and P = 0.75) for
the low and the high bacterial inocula, respectively.
The bactericidal effects of both MGHs were investi-
gated regarding the MBC (Figure 1). For MGH1, at low
inoculum concentration, an MBC of 10% (w/v) was
observed for the majority of isolates tested, except for
three isolates which showed an MBC of 20% (w/v). How-
ever, at high bacterial load, only two isolates presented
an MBC of 10% (w/v), whereas most had an MBC of
20% (w/v).
For MGH2, the MBC values at low bacterial concentra-
tion were dispersed; ranging from 5% to 40% (w/v); two
with an MBC of 5% (w/v), three at 10% (w/v), four at
20% (w/v) and two at 40% (w/v). This dispersion was not
detected at the high bacterial concentration, where all iso-
lates showed an MBC of 40% (w/v). Neither MGH was
effective in killing two isolates (MRSP FMV 4877/10 and
MRSP GV818/2017) at the high inoculum concentration.
Overall, MGH1 had a significantly stronger bactericidal
effect compared to MGH2 at the high inoculation concen-
tration (P = 0.0039) , whereas at low bacterial concentra-
tion no significant difference between the MGHs was
found (P = 0.125).
In vitro efficacy of MGHs against Pseudomonas spp.
The MICs of MGH1 against Pseudomonas spp. were sig-
nificantly lower compared to MGH2 at both bacterial con-
centrations (P = 0.0020 low and P = 0.0039 high;
Figure 2). At both bacterial concentrations and for all
Pseudomonas isolates, MGH1 had a MIC of 20% (w/v),
whereas MGH2 showed a MIC of 20% (w/v) for only one
strain (P. aeruginosa ATCC 15442) and a MIC of 40% (w/
v) against the 10 remaining isolates, except for the isolate
Table 1. Overview of staphylococcal and Pseudomonas strains used in this study
Strain Clonal lineage
Antimicrobial and biocide
resistance genes Origin Type of Infection Reference
MSSA ATCC 6538TM ST464-t3297 - Human Human lesion ATCC51
MSSA ATCC 29213TM - -- Human Skin wound ATCC
MSSA FMV 77/2015 ND ND Dog Skin infection 31,33
MRSA FMV 1504A/08 ST22-t032-SCCmec
type IV
blaZ, mecA Dog Skin infection 32
MRSA SM39 ST88-t186 blaZ, cadA, qacA Human Nosocomial infection 29,30,52
MRSA SM52 ST8-t008 Smr, GrlA: S80Y, GyrA: S84L Human Nosocomial infection 30
MRSP FMV 4877/10 ST71-t02-SCCmec
type II-II
blaZ, mecA, erm(B), tet(K),
aacA-aphD, aphA3, aadE, dfr(G)
Dog Skin infection 31,33
MRSP FMV 56/2013A SCCmec type III erm(b), tet(M), aphA3, aadE Dog Skin infection FMV-UL
MRSP GV818/2017 ND ND Dog Skin infection Genevet Biobank
MRSE FMV 60/2012 ST5-SCCmec
type IV
blaZ, mecA, erm(C), tet(K),
aacA-aphD, fusB
Dog Skin infection 33
MRSS FMV 57/2013B SCCmec type III blaZ, mecA, tet(K) Dog Skin infection 33
P. aeruginosa ATCC27853TM ND ND Human Blood culture ATCC
P. aeruginosa ATCC15442TM ND ND Animal Animal room bottle ATCC
P. aeruginosa FMV114/2014 ND ND Dog OE FMV-UL
P. aeruginosa FMV74/2015 ND ND Dog OE FMV-UL
P. fluorescens FMV85/2015 ND ND Dog OE FMV-UL
P. fluorescens FMV147/2015 ND ND Dog OE FMV-UL
P. aeruginosa FMV26/2016 ND ND Dog OE FMV-UL
P. aeruginosa FMV27/2016 ND ND Dog OE FMV-UL
P. aeruginosa FMV49/2016 ND ND Dog OE FMV-UL
P. aeruginosa FMV02/2017 ND ND Dog OE FMV-UL
P. aeruginosa FMV42/2017 ND ND Dog OE FMV-UL
ATCC, American Type Culture Collection; FMV, Faculty of Veterinary Medicine (University of Lisbon); MRSA, meticillin-resistant Staphylococcus
aureus; MRSE, meticillin-resistant Staphylococcus epidermidis; MRSP, meticillin-resistant S. pseudintermedius; MRSS, meticillin-resistant Sta-
phylococcus schleiferi; MSSA, meticillin-susceptible S. aureus; ND, not done; OE, otitis externa.
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FMV74/2015 that was not susceptible at high bacterial
load.
MGH1 also had significantly lower MBCs for the Pseu-
domonas isolates compared to MGH2 at the low bacterial
concentration (P = 0.0459), whereas there was no statis-
tical significance at the high bacterial concentration
(P = 0.0918; Figure 2). At the low inoculum concentra-
tion, one isolate (P. aeruginosa FMV27/2016) could not
be killed by MGH1 and at the high bacterial concentration
one additional isolate (P. aeruginosa FMV74/2015) was
not susceptible to MGH1. This same isolate showed no
growth inhibition by either MGH at the high bacterial
inoculum. Against all other isolates, the MBC of MGH1
was 20% (w/v). Regarding MGH2, independent of bacte-
rial load, the MBC was 40% (w/v) for all Pseudomonas
isolates, except for P. aeruginosa FMV74/2015, which
was not susceptible to MGH2 at the high concentration.
Discussion
The present study has shown that two different MGH for-
mulations are effective against most Staphylococcus spp.
and Pseudomonas spp. isolates tested. Staphylococcal
strains were specifically selected that are commonly
implicated in human and canine infections and present
relevant resistance phenotypes and genotypes. Two
Figure 1. Minimal inhibitory concentration (MIC) and minimal biocidal concentration (MBC) for medical grade honey (MGH) formulations MGH1
and MGH2 against 11 staphylococcal isolates originating from human and canine skin infections.
Each symbol represents a different isolate. Mean values were plotted for each bacterial isolate; tests were performed in triplicate at each concen-
tration of the product and at both bacterial loads. There were no significant differences observed between the MICs of the two MGH formulations
at the two different bacterial loads. MGH1 showed a significantly stronger bactericidal effect compared to MGH2 at the high bacterial load
(**P < 0.01). Nevertheless, both MGH1 and MGH2 were ineffective against high bacterial concentrations of the MRSP FMV 4877/10 and MRSP
GV818/2017. The isolates that were not sensitive were not plotted in the graph but were included in the statistical analysis.
Figure 2. Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) for medical grade honey (MGH) formulations
MGH1 and MGH2 against 11 Pseudomonas spp. isolates originating from canine ear infections.
Each symbol represents a different isolate. The minimal concentration of MGH1 to exert bacteriostatic effects was significantly lower than this of
MGH2 at both low and high bacterial load (**P < 0.01). Mean values were plotted for each bacterial isolate; tests were performed in triplicate at
each concentration of the product and at both bacterial loads. At the high bacterial inoculation load, MGH1 and MGH2 were ineffective to inhibit
the growth of P. aeruginosa FMV74/2015. The isolates that were not sensitive were not plotted in the graph but were included in the statistical
analysis. The minimal concentration of MGH1 to exert a bactericidal effect at the low bacterial load was lower than for MGH2 (*P < 0.05), whereas
there was no statistically significant difference at the high concentration. Pseudomonas aeruginosa FMV27/2016 was not affected by MGH1 at
both bacterial loads. At low bacterial load, P. aeruginosa FMV74/2015 was not killed by MGH2; at high bacterial load, this isolate was killed neither
by MGH1 nor MGH2. Isolates that were not sensitive were not plotted in the graph but were included in the statistical analysis.
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P. fluorescens isolates were included in the Pseu-
domonas collection even though this species may be less
pathogenic than P. aeruginosa, because P. fluorescens
also may be isolated from skin infections where it causes
a putrid malodour.37 Furthermore, the methods devel-
oped and validated in this study were based on CLSI
guidelines but with the addition of an extra bacterial con-
centration resembling the cutaneous in vivo bacterial load
expected during skin and ear canal infections.34–36 The
105 cfu/g of tissue (“105 guideline”) is widely adopted
and is a consensus for the definition of bacterial skin
infection.25 The lower bacterial load investigated in the
present study better resembles the bacterial load during a
systemic infection.
It was demonstrated herein that both MGH formula-
tions presented low MICs and MBCs, suggesting that
those MGHs also could be effective for topical treatment
of infections caused by the tested bacteria, including
staphylococci expressing MR, MDR and reduced biocide
susceptibility, and Pseudomonas spp. isolates expressing
MDR. It should be noted that residual MGH on the agar
plate could possibly have led to an overestimation of the
MBC values; however, this effect would have been simi-
lar for both MGH formulations.
Typically, MGH1 was bacteriostatic and bactericidal at
a concentration of 10% (w/v) against staphylococci, and
at a concentration of 20% (w/v) against most of the
tested Pseudomonas spp. isolates. MGH2 showed more
isolate-dependent variation in antimicrobial efficacy,
although sometimes a higher inhibitory effect (lower
MIC) was obtained with MGH2 compared to MGH1.
However, MGH1 consistently showed a stronger bacteri-
cidal effect (lower MBC), especially against the high con-
centration of bacteria as may be encountered with
cutaneous infections. Interestingly, MGH1 was more
effective than MGH2 against all Pseudomonas spp. iso-
lates in both MIC and MBC. The higher efficiency of
MGH1 against Pseudomonas spp. and its consistent
effects against staphylococcal isolates, suggest that
MGH1 has stronger and more versatile antimicrobial
effects than MGH2. The honey concentrations in these
two MGHs differ, with MGH2 being twice as concen-
trated (80% w/v) as MGH1 (40% w/v). Therefore, lower
concentrations of honey in MGH1 exerted stronger or at
least similar biocidal action compared to the honey in
MGH2. A formulation with a lower but more effective
honey concentration might prove to be more advanta-
geous in clinical cases because high concentrations of
honey may lead to stronger osmotic effects that could
result in the sensation of stinging pain.38
The observed difference in antimicrobial effects
between MGH1 and MGH2 may be explained by the dif-
ferent types of honey in their formulations having differ-
ent mechanisms of action. Variation in antimicrobial
activity may exist between honey types, but also may
change between bacterial isolates, as is shown by the
variability in efficacy of MGH2 against S. aureus. Neutral-
ization of methylglyoxal in Manuka honey has been
shown to eliminate the antimicrobial effects towards
S. aureus,14 supporting the hypothesis that MGH2 would
depend specifically on methylglyoxal. MGH1 contains
lower levels of methylglyoxal, but acts via other
components, such as hydrogen peroxide, bee defensin-1,
low pH, sugars and high osmolarity.39,40
MGH1 previously has been evaluated in a pilot clinical
trial which reported favourable antibacterial potential in
canine otitis externa.41 In addition, MGH1 has been evalu-
ated in vitro reiterating its antifungal and antibacterial prop-
erties via a hydrogen peroxide-independent action.2 In that
study, MGH1 was compared to honey, showing that
MGH1 had a significantly stronger bactericidal effect than
honey alone against S. pseudintermedius isolates
(P = 0.003). Sixteen of the 60 isolates tested had a lower
MBC for MGH1 compared to honey. A range of 5–20%w/
v for MGH1 was observed and no difference was seen
between MSSP and MRSP isolates.2 This is in line with
the observations herein, with MGH1 typically having an
MBC of 10–20% against MRSP.MGH1 has been reported
to show antifungal activity against Candida albicans, com-
pared with raw honey, suggesting that supplemented vita-
mins may enhance antimicrobial properties.42 In a
randomized controlled trial with 127 horses having lacera-
tions, MGH1 was able to prevent infections and improve
complete healing and veterinarian satisfaction.43
Infected wounds often contain polymicrobial patho-
gens44,45 and therefore an antimicrobial agent active
against a wide spectrum of pathogens is warranted. The
broad response of almost all the isolates tested in the pre-
sent work against both MGHs suggests that they might
have therapeutic efficacy in a variety of pathologies and
that it should be considered for treatment of wounds and
otitis externa. Because MGH1 can prevent infections43
the prophylactic use of MGH in surgical wounds or pri-
mary closure of wounds also forms an interesting strat-
egy. Nevertheless, both MGH formulations showed that
certain isolates were less susceptible, suggesting that
not every infection will respond to the same extent to the
MGH therapy.
Besides its antimicrobial effects, honey also possesses
good wound-healing properties and stimulates tissue
growth, has immunomodulatory effects, resolves inflam-
mation, enhances angiogenesis and epithelialization, and
minimizes scar formation.46,47 The addition of supple-
ments to MGH formulations may further enhance the
pro-healing effects of MGH while possibly improving its
antimicrobial properties.42,47 MGH1 is supplemented
with vitamins C and E that act synergistically and enhance
wound repair10–12 and its antimicrobial activity.42,48 Vita-
min C is a cofactor in the biosynthesis of collagen and
improves angiogenesis and tensile strength in the
skin.49,50 Vitamin E protects cells from lipid peroxidation,
is anti-inflammatory and reduces scar formation.11 MGH
supplemented with these vitamins should be considered
for both infected and clean wounds. Further investigation
into the effects of MGH on cellular and molecular targets
is needed, and the in vivo broad-range antimicrobial effi-
cacy needs to be confirmed in clinical trials.
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Table S1. Interpretive results of MIC breakpoints (mg/L)
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Resume
Contexte – La resistance antimicrobienne est un probleme en sante humaine et animale. Le miel pourrait
e^tre utilise pour ses proprietes de cicatrisation et ses effets antimicrobiens.
Objectif – Etudier l’activite antimicrobienne de deux miels medicaux disponibles dans le commerce
(MGHs) contre les souches de Staphylococcus spp. et Pseudomonas spp.
Materiels et methodes – Deux formulations, MGH1 (miel a 40% w/v) et MGH2 (miel de Manuka a 80%
w/v), ont ete testees in vitro pour la concentration minimale inhibitrice (MIC) et les concentrations minima-
les bactericides (MBC) contre 11 souches de Staphylococcus et 11 Pseudomonas a faibles [1.5 9 104 col-
ony forming units (cfu)/well] et hautes (1.5 9 106 cfu/well) concentrations d’inoculum, representant
respectivement une charge bacterienne systemique et cutanee au cours de l’infection.
Resultats – MGH2 a montre une MIC plus faible que MGH1 contre staphylococci, bien que ce ne soit pas
statistiquement significatif. MGH1 a des effets bactericides plus forts contre staphylococci que MHG2,
bien que cet effet ne soit statistiquement significatif qu’a la concentration bacterienne la plus elevee (P <
0.01). Pour Pseudomonas spp., MGH1 avait une activite antimicrobienne significativement plus elevee
(MIC et MBC) que MGH2 contre toutes les souches testees et aux deux concentrations bacteriennes (P <
0.05).
Conclusions et importance clinique – Les deux MGHs etaient efficaces in vitro contre les pathogenes
cutanes frequents incluant les staphylocoques resistant a la meticilline et Pseudomonas. La plus grande
efficacite de la formulation de MGH1 contre Pseudomonas et ses effets contre staphylocoques, alors que
contenant moitie moins de mile que MGH2, implique la realisation d’autres etudes des mecanismes et des
applications cliniques de MGH1.
Resumen
Introduccion – la resistencia a los antimicrobianos es un problema en la salud humana y animal. La miel
puede usarse por sus propiedades de cicatrizacion en heridas y por sus efectos antimicrobianos.
Objetivo – investigar la actividad antimicrobiana de dos mieles de grado medico (MGHs) disponibles
comercialmente frente a aislados de Staphylococcus spp. y Pseudomonas spp.
Metodos y materiales – dos formulaciones, MGH1 (40% p/v de miel) y MGH2 (80% p/v de miel de Man-
uka), se probaron in vitro para detectar concentraciones inhibitorias mınimas (MIC) y concentraciones bac-
tericidas mınimas (MBC) frente a 11 aislados de Staphylococcus y 11 aislados de Pseudomonas a bajas
[1,5 9 104 unidades formadoras de colonias (cfu)/pocillo] y altas (1,5 9 106 cfu/pocillo) concentraciones de
inoculo, que representan cargas bacterianas sistemicas y cutaneas durante la infeccion, respectivamente.
Resultados – MGH2 mostro una menor MIC frente a estafilococos que MGH1, aunque esto no fue
estadısticamente significativo. MGH1 tuvo efectos bactericidas mas potentes frente a estafilococos que
MGH2, aunque este efecto fue estadısticamente significativo solo a la concentracion bacteriana mas alta
(P <0,01). Para Pseudomonas spp., MGH1 tuvo una actividad antimicrobiana significativamente mayor
(tanto MIC como MBC) que MGH2 frente a todos los aislamientos probados y en ambas concentraciones
bacterianas (P <0,05).
Conclusiones e importancia clınica – Ambas formulaciones de MGH fueron efectivas in vitro frente a
patogenos cutaneos comunes, incluidos los estafilococos resistentes a meticilina y especies de Pseudo-
monas. La mayor eficacia de la formulacion de MGH1 frente a Pseudomonas y sus efectos consistentes
frente a estafilococos, aun teniendo solo la mitad de la cantidad de miel en comparacion con MGH2, invita
a una mayor investigacion de los mecanismos y aplicaciones clınicas de MGH1.
Zusammenfassung
Hintergrund – Die antimikrobielle Resistenz ist ein Problem bei der Gesundheitsvorsorge des Menschen
und der Tiere. Honig k€onnte aufgrund seiner Wundheilungseigenschaften und antimikrobieller Wirkungs-
weisen Verwendung finden.
Ziel – Eine Untersuchung der antimikrobiellen Aktivit€at zweier kommerziell verf€ugbarer medizinischer Hon-
ige (MGHs) im Einsatz gegen Staphylococcus spp. und Pseudomonas spp. Isolate.
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Methoden und Materialien – Zwei Formulierungen, MGH1 (40% w/v Honig) und MGH2 (80% w/v Manu-
kahonig) wurden in vitro auf ihre minimale Hemmstoffkonzentration (MIC) und minimale bakterizide Kon-
zentration (MBC) gegen€uber Staphylococcus und 11 Pseudomonas Isolate getestet, wobei niedrige[1,5 x
104 Kolonie-bildende Einheiten (cfu)/Prober€ohrchen] und hohe (1,5 x 106 cfu/ Prober€ohrchen) Konzentratio-
nen von Inokulum eingesetzt wurden, was systemische bzw kutane bakterielle Belastungen w€ahrend einer
Infektion repr€asentierte .
Ergebnisse – MGH2 zeigte eine niedrigere MIC gegen€uber Staphylokokken als MGH1, obwohl dieses
Ergebnis nicht statistisch signifikant war. MGH1 zeigte eine deutlichere bakterizide Wirkung gegen€uber
Staphylokokken als MGH2, obwohl dieses Ergebnis nur bei h€oheren bakteriellen Konzentrationen statis-
tisch signifikant war (P < 0,01). Bei Pseudomonas spp. zeigte MGH1 eine signifikant h€ohere antimikrobielle
Aktivit€at (sowohl MIC als auch MBC) als MGH2 gegen€uber allen getesteten Isolaten und bei beiden bakte-
riellen Konzentrationen (P < 0,05).
Schlussfolgerungen und klinische Bedeutung – Beide MGHs waren in vitro gegen €ubliche Hautpatho-
gene inklusive Methicillin-resistenten Staphylokokken und Pseudomonas Spezies wirksam. Die h€ohere
Wirksamkeit der MGH1 Formulierung gegen€uber Pseudomonas und seine konstante Wirkung gegen€uber
Staphylokokken, obwohl es nur die halbe Menge an Honig im Vergleich zu MGH2 beinhaltete, laden zu wei-
terer Untersuchung des Mechanismus und der klinischen Anwendung von MGH1 ein.
要約
背景 – 抗菌薬耐性は、人間および動物のヘルスケアにおける問題である。蜂蜜は、その創傷治癒特性お
よび抗菌効果のために使用される場合がある。
目的 – 本研究の目的は、2つの市販された医療グレードの蜂蜜(MGH)によるブドウ球菌およびシュードモ
ナス属菌株に対する抗菌活性を調査することである。
材料と方法 – MGH1(40%w / v蜂蜜)とMGH2(80%w / vのマヌカ蜂蜜)の2製剤に対し、それぞれ感染時の全
身および皮膚細菌負荷を表す、低濃度[1.59104コロニー形成単位(cfu)/ウェル]および高濃度(1.59106 cfu /
ウェル)のブドウ球菌および緑膿菌それぞれ11分離株に対する最小発育阻止濃度(MIC)と最小殺菌濃度
(MBC)をin vitroでテストした。
結果 – MGH2は、MGH1よりもブドウ球菌に対する低いMICを示したが、統計的に有意ではなかった。
MGH1はMGH2よりブドウ球菌に対して強い殺菌効果があったが、細菌濃度が濃い場合にのみ統計的に有
意であった(P <0.01)。緑膿菌においては、MGH1は、試験した全分離株および両細菌濃度で、MGH2より
も抗菌活性(MICおよびMBCの両方)が有意に高かった(P <0.05)。
結論と臨床的重要性 – 両MGHは、メチシリン耐性ブドウ球菌と緑膿菌を含む一般皮膚病原体に対して
in vitroで効果的であった。 MGH2と比較し、半量の蜂蜜しか含まない一方で、緑膿菌に対するMGH1製
剤の高い効力およびブドウ球菌に対する一貫した効果は、MGH1のメカニズムおよび臨床応用のさらな
る調査をもたらす。
摘要
背景 – 抗生素耐药性是人类和动物医疗保健中的一个问题。由于蜂蜜具有愈合伤口和抗菌作用,因而值得使
用。
目的 – 研究现有市售的两种药用级别蜂蜜(MGHs)对葡萄球菌和假单胞菌分离株的抗菌活性。
方法和材料 –两种配方,MGH1 (40% w/v蜂蜜)和MGH2 (80% w/v Manuka蜂蜜),针对11个葡萄球菌和11
个假单胞菌分离株,体外测定其最小抑制浓度(MIC)和最小杀菌浓度(MBC),选择培养液的低 [1.5 9 104 col-
ony forming units (cfu)/well]和高 (1.5 9 106 cfu/well) 浓度,分别代表感染期间全身和皮肤的细菌量。
结果 – MGH2对葡萄球菌的MIC低于MGH1,尽管这没有统计意义。MGH1对葡萄球菌的杀菌作用强于
MGH2,但这个结果仅在细菌浓度高时才有统计意义(P < 0.01)。对于假单胞菌,MGH1对所有被测菌株的抗
菌活性(MIC和MBC)均高于MGH2,且在两种细菌浓度下均高于MGH2 (P < 0.05)。
结论和临床意义 – 在体外试验中,两种MGHs对常见的皮肤致病菌,包括耐甲氧西林葡萄球菌和假单胞菌均
有效。与MGH2相比,MGH1配方对假单胞菌疗效更高,且具有持续对抗葡萄球菌的作用,但其蜂蜜含量仅为
MGH2的一半。因此,MGH1的作用机制和临床应用有待进一步研究。
Resumo
Contexto – A resiste^ncia antimicrobiana e um problema na saude humana e animal. O mel pode ser utili-
zado por suas propriedades curativas e efeitos antimicrobianos.
Objetivo – Investigar a atividade antimicrobiana de dois meis medicinais (MGHs) comercialmente dis-
ponıveis contra Staphylococcus spp. e Pseudomonas spp. isolados.
Metodos e materiais – Duas formulac~oes, MGH1 (40% p / v mel) e MGH2 (80% p / v mel Manuka), foram
testadas in vitro para concentrac~oes inibitorias mınimas (MIC) e concentrac~oes bactericidas mınimas
(MBC) contra 11 Staphylococcus e 11 Pseudomonas isolados em baixas [1,5 9 104 unidades formadoras
de colo^nias (ufc) / poco] e altas (1,5 9 106 ufc / poco) concentrac~oes de inoculo, representando cargas bac-
terianas siste^micas e cuta^neas durante a infecc~ao, respectivamente.
Resultados – O MGH2 mostrou uma MIC menor contra estafilococos do que o MGH1, embora isso n~ao
tenha sido estatisticamente significativo. O MGH1 teve efeitos bactericidas mais fortes contra os
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estafilococos do que o MGH2, embora esse efeito tenha sido estatisticamente significativo apenas na
maior concentrac~ao bacteriana (P <0,01). Para Pseudomonas spp., O MGH1 apresentou atividade antimi-
crobiana significativamente maior (MIC e MBC) do que o MGH2 contra todos os isolados testados e em
ambas as concentrac~oes bacterianas (P <0,05).
Conclus~oes e importa^ncia clınica – Ambas OS MGHs foram eficazes in vitro contra patogenos cuta^neos
comuns, incluindo estafilococos resistentes a meticilina e especies de Pseudomonas. A maior eficacia da
formulac~ao MGH1 contra Pseudomonas e seus efeitos consistentes contra estafilococos, embora conte-
nha apenas metade da quantidade de mel em comparac~ao com o MGH2, convida a uma investigac~ao mais
aprofundada dos mecanismos e aplicac~oes clınicas do MGH1.
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